American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy

Brachytherapy

Volumn 11, Issue 1, 2012, Pages 6-19

  Davis, Brian J ^a   Horwitz, Eric M ^b   Lee, W Robert ^c   Crook, Juanita M ^d   Stock, Richard G ^e   Merrick, Gregory S ^f   Butler, Wayne M ^f   Grimm, Peter D ^g   Stone, Nelson N ^e   Potters, Louis ^h   Zietman, Anthony L ⁱ   Zelefsky, Michael J ^j  

^a MAYO CLINIC   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f WHEELING JESUIT UNIVERSITY   (United States)

^g Prostate Cancer Treatment Center   (United States)

^h North Shore LIJ Health System   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

Brachytherapy; Dosimetry; Guideline; Interstitial; Prostate cancer; Quality assurance; Radiation therapy; Radiotherapy; Safety; Standard

Indexed keywords

CESIUM 131; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE;

ARTICLE; BRACHYTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; CYSTOSCOPY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; MEDICAL HISTORY; MEDICAL SOCIETY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PERMANENT PROSTATE BRACHYTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOISOTOPE THERAPY; SEMINAL VESICLE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT CONTRAINDICATION; TREATMENT PLANNING;

BRACHYTHERAPY; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, INTERVENTIONAL; UNITED STATES;

EID: 84862908703     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2011.07.005     Document Type: Article

References (167)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics. CA Cancer J Clin 2010, 60:277-300.
2. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer V.3.2010. Available at: Accessed July 16, 2011. http://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf.
3. Charyulu K.K. Transperineal interstitial implantation of prostate cancer: A new method. Int J Radiat Oncol Biol Phys 1980, 6:1261-1266.
4. Holm H.H. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol 1997, 13:431-437.
5. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007, 67:57-64.
6. Lehrer S., Cesaretti J., Stone N.N., et al. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. BJUInt 2006, 98:979-981.
7. Sharkey J., Cantor A., Solc Z., et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: A 12-year experience from a single group practice. Brachytherapy 2005, 4:34-44.
8. Critz F.A., Levinson K. 10-year disease-free survival rates after simultaneous irradiation for prostate cancer with a focus on calculation methodology. J Urol 2004, 172:2232-2238.
9. Dattoli M., Wallner K., True L., et al. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension. Urology 2007, 69:334-337.
10. Taira A.V., Merrick G.S., Butler W.M., et al. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 79:1336-1342.
11. NCI. Prostate Cancer Treatment-treatment option overview. National Cancer Institute Web site. Available at: Accessed July 23, 2011. http://www.cancer.gov/cancertopics/pdq/treatment/prostate/Patient/page4.
12. Initial treatment of prostate cancer by stage. American Cancer Society Web site. Available at: Accessed July 23, 2011. http://www.cancer.org/Cancer/ProstateCancer/DetailedGuide/prostate-cancer-treating-by-stage.
13. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 Update. J Urol 2007, 177:2106-2131.
14. Rosenthal S.A., Bittner N.H.J., Beyer D.C., et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79:335-341.
15. Ash D., Flynn A., Battermann J., et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000, 57:315-321.
16. Goharderakhshan R.Z., Grossfeld G.D., Kassis A., et al. Additional treatments and reimbursement rates associated with prostate cancer treatment for patients undergoing radical prostatectomy, interstitial brachytherapy, and external beam radiotherapy. Urology 2000, 56:622-626.
17. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44:789-799.
18. Lee W.R., DeSilvio M., Lawton C., et al. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: Preliminary results of RTOG P-0019. Int J Radiat Oncol Biol Phys 2006, 64:804-809.
19. Feigenberg S.J., Lee W.R., Desilvio M.L., et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 2005, 62:956-964.
20. Crook J.M., Gomez-Iturriaga A., Wallace K., et al. Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol 2011, 29:362-368.
21. Hurwitz M.D., Halabi S., Ou S.-S., et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: An initial report of CALGB 99809. Int J Radiat Oncol Biol Phys 2008, 72:814-819.
22. Nag S., Bice W., DeWyngaert K., et al. The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int J Radiat Oncol Biol Phys 2000, 46:221-230.
23. Nag S., Ellis R.J., Merrick G.S., et al. American Brachytherapy Society recommendations for reporting morbidity after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 54:462-470.
24. Nath R., Bice W.S., Butler W.M., et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137. Med Phys 2009, 36:5310-5322.
25. Rosenthal S.A., Bittner N.H.J., Beyer D.C., et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2011, 79:335-341.
26. Lee W.R., Bae K., Lawton C., et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: Analysis of Radiation Therapy Oncology Group study 0019. Cancer 2007, 109:1506-1512.
27. Lee W.R., Bae K., Lawton C.A., et al. A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. Brachytherapy 2006, 5:239-243.
28. Ghaly M., Wallner K., Merrick G., et al. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2003, 55:1288-1293.
29. Narayana V., Troyer S., Evans V., et al. Randomized trial of high- and low-source strength (125)I prostate seed implants. Int J Radiat Oncol Biol Phys 2005, 61:44-51.
30. Barry M.J., Fowler F.J., Bin L., et al. A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer. J Urol 1997, 158:488-491. discussion 492.
31. Edge S.B., Byrd D.R., Compton C.C., et al. AJCC Cancer Staging Manual 2010, Springer, New York. 7th ed.
32. Wallner K., Simpson C., Roof J., et al. Local anesthesia for prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 45:401-406.
33. Rockhill J., Wallner K., Hoffman C., et al. Prostate brachytherapy in obese patients. Brachytherapy 2002, 1:54-60.
34. Merrick G.S., Butler W.M., Wallner K.E., et al. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy. Urology 2005, 65:95-100.
35. Skolarus T.A., Wolin K.Y., Grubb R.L. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol 2007, 4:605-614.
36. Efstathiou J.A., Skowronski R.Y., Coen J.J., et al. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71:1302-1308.
37. Koutrouvelis P.G., Theodorescu D., Katz S., et al. Brachytherapy of prostate cancer after colectomy for colorectal cancer: Pilot experience. J Urol 2005, 173:82-85. discussion 85-86.
38. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002, 52:453-460.
39. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. Int J Radiat Oncol Biol Phys 2006, 64:825-834.
40. Terk M., Stock R., Stone N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998, 160:1379-1382.
41. Lee N., Wuu C.S., Brody R., et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 48:1457-1460.
42. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 2002, 52:712-719.
43. Schwartz D.J., Schild S.E., Wong W.W., et al. Factors associated with the frequency of self-intermittent catheterization after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:60-63.
44. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002, 53:91-98.
45. Merrick G.S., Butler W.M., Lief J.H., et al. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000, 47:121-128.
46. Gutman S., Merrick G.S., Butler W.M., et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 2006, 97:62-68.
47. Martens C., Pond G., Webster D., et al. Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy. Brachytherapy 2006, 5:9-13.
48. Thomas C., Keyes M., Liu M., et al. Segmental urethral dosimetry and urinary toxicity in patients with no urinary symptoms before permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008, 72:447-455.
49. Williams S.G., Millar J.L., Duchesne G.M., et al. Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy. Radiother Oncol 2004, 73:33-38.
50. Ikeda T., Shinohara K. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: Our experience and literature review. Int J Urol 2009, 16:558-560.
51. Davis B.J., Wilson T.M., Mynderse L.A., et al. Analysis of pretreatment factors predictive of urinary morbidity following permanent prostate brachytherapy (PPB) including cystoscopic findings and uroflowmetry. Radiother Oncol 2005, 75:S28.
52. Wehle M.J., Lisson S.W., Buskirk S.J., et al. Prediction of genitourinary tract morbidity after brachytherapy for prostate adenocarcinoma. Mayo Clin Proc 2004, 79:314-317.
53. Wallner K., Lee H., Wasserman S., et al. Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int J Radiat Oncol Biol Phys 1997, 37:565-569.
54. Stone N.N., Ratnow E.R., Stock R.G. Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Tech Urol 2000, 6:123-127.
55. Moran B.J., Stutz M.A., Gurel M.H. Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 2004, 59:392-396.
56. Merrick G.S., Butler W.M., Wallner K.E., et al. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004, 58:81-88.
57. Bellon J., Wallner K., Ellis W., et al. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 43:579-581.
58. Wallner K., Ellis W., Russell K., et al. Use of TRUS to predict pubic arch interference of prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 43:583-585.
59. Tincher S.A., Kim R.Y., Ezekiel M.P., et al. Effects of pelvic rotation and needle angle on pubic arch interference during transperineal prostate implants. Int J Radiat Oncol Biol Phys 2000, 47:361-363.
60. Henderson A., Laing R.W., Langley S.E.M. Identification of pubic arch interference in prostate brachytherapy: Simplifying the transrectal ultrasound technique. Brachytherapy 2003, 2:240-245.
61. Gibbons E.P., Smith R.P., Beriwal S., et al. Overcoming pubic arch interference with free-hand needle placement in men undergoing prostate brachytherapy. Brachytherapy 2009, 8:74-78.
62. Petit J.H., Gluck C., Kiger W.S., et al. Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume. Brachytherapy 2007, 6:267-271.
63. Solhjem M.C., Davis B.J., Pisansky T.M., et al. Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J 2004, 10:343-348.
64. Kucway R., Vicini F., Huang R., et al. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol 2002, 167:2443-2447.
65. Beyer D.C., McKeough T., Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:1299-1305.
66. Crook J., Ludgate C., Malone S., et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:15-23.
67. Grado G.L. Techniques to achieve optimal seed placement in salvage and primary brachytherapy for prostate cancer. Tech Urol 2000, 6:157-165.
68. Landis D.M., Schultz D., Cormack R., et al. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology 2005, 65:750-754.
69. Gibbons E.P., Jacobs B.L., Smith R.P., et al. Dosimetric outcomes in prostate brachytherapy: Is downsizing the prostate with androgen deprivation necessary?. Brachytherapy 2009, 8:304-308.
70. Linzer D.G., Stock R.G., Stone N.N., et al. Seminal vesicle biopsy: Accuracy and implications for staging of prostate cancer. Urology 1996, 48:757-761.
71. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001, 51:31-40.
72. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005, 173:1562-1566.
73. Stone N.N., Potters L., Davis B.J., et al. Customized dose prescription for permanent prostate brachytherapy: Insights from a multicenter analysis of dosimetry outcomes. Int J Radiat Oncol Biol Phys 2007, 69:1472-1477.
74. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
75. Stone N.N., Stock R.G. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. J Urol 2007, 177:925-928.
76. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: Implications for prostate brachytherapy. Cancer 1999, 85:2630-2637.
77. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 2000, 55:382-386.
78. Teh B.S., Bastasch M.D., Mai W.-Y., et al. Predictors of extracapsular extension and its radial distance in prostate cancer: Implications for prostate IMRT, brachytherapy, and surgery. Cancer J 2003, 9:454-460.
79. Chao K.K., Goldstein N.S., Yan D., et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 2006, 65:999-1007.
80. Sengupta S., Davis B.J., Mynderse L.A., et al. Permanent prostate brachytherapy: Pathologic implications as assessed on radical prostatectomy specimens of broadening selection criteria for monotherapy. Urology 2006, 68:810-814.
81. Butzbach D., Waterman F.M., Dicker A.P. Can extraprostatic extension be treated by prostate brachytherapy? An analysis based on postimplant dosimetry. Int J Radiat Oncol Biol Phys 2001, 51:1196-1199.
82. Davis B.J., Haddock M.G., Wilson T.M., et al. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: Is extraprostatic seed placement necessary?. Tech Urol 2000, 6:70-77.
83. Frank S.J., Grimm P.D., Sylvester J.E., et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 2007, 6:2-8.
84. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
85. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-Year results of an EORTC randomised study. The Lancet Oncology 2010, 11:1066-1073.
86. Merrick G.S., Wallner K.E., Butler W.M. Permanent interstitial brachytherapy for the management of carcinoma of the prostate gland. JUrol 2003, 169:1643-1652.
87. Merrick G.S., Butler W.M., Wallner K.E., et al. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 2007, 68:34-40.
88. Stone N.N., Potters L., Davis B.J., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 73:341-346.
89. Stock R.G., Lo Y.C., Gaildon M., et al. Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined pd-103 prostate implantation and external beam irradiation. Int J Radiat Oncol Biol Phys 1999, 45:385-389.
90. Goldstein N.S., Kestin L.L., Vicini F.A., et al. The influence of percentage of preradiation needle biopsies with adenocarcinoma and total radiation dose on the pathologic response of unfavorable prostate adenocarcinoma. Am J Clin Pathol 2002, 117:927-934.
91. Davis B., Cheville J., Wilson T., et al. Histopathologic characterization of seminal vesicle invasion in prostate cancer: Implications for radiotherapeutic management. Int J Radiat Oncol Biol Phys 2001, 51:140-141.
92. Ho A.Y., Burri R.J., Jennings G.T., et al. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Brachytherapy 2007, 6:38-43.
93. Nag S., Ciezki J.P., Cormack R., et al. Intraoperative planning and evaluation of permanent prostate brachytherapy: Report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2001, 51:1422-1430.
94. Stone N.N., Stock R.G. Brachytherapy for prostate cancer: Real-time three-dimensional interactive seed implantation. Tech Urol 1995, 1:72-80.
95. Fogh S., Doyle L., Yu A., et al. A comparison of preplan transrectal ultrasound with preplan-CT in assessing volume and number of seeds needed for real-time ultrasound-based intra-operative planning in prostate (125)I seed implantation. Brachytherapy 2010, 9:335-340.
96. Crook J.M., Potters L., Stock R.G., et al. Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy 2005, 4:186-194.
97. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001, 50:335-341.
98. Prestidge B.R., Prete J.J., Buchholz T.A., et al. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Int J Radiat Oncol Biol Phys 1998, 40:461-465.
99. Orio P.F., Tutar I.B., Narayanan S., et al. Intraoperative ultrasound-fluoroscopy fusion can enhance prostate brachytherapy quality. Int J Radiat Oncol Biol Phys 2007, 69:302-307.
100. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002, 12:81-94.
101. Battermann J.J., van Es C.A. The learning curve in prostate seed implantation. Cancer Radiother 2000, (4 Suppl. 1):119s-122s.
102. Older R.A., Synder B., Krupski T.L., et al. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy. J Urol 2001, 165:1590-1592.
103. Tapen E.M., Blasko J.C., Grimm P.D., et al. Reduction of radioactive seed embolization to the lung following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998, 42:1063-1067.
104. Merrick G.S., Butler W.M., Dorsey A.T., et al. Seed fixity in the prostate/periprostatic region following brachytherapy. Int J Radiat Oncol Biol Phys 2000, 46:215-220.
105. Eshleman J.S., Davis B.J., Pisansky T.M., et al. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys 2004, 59:419-425.
106. Al-Qaisieh B., Carey B., Ash D., et al. The use of linked seeds eliminates lung embolization following permanent seed implantation for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:397-399.
107. Fuller D.B., Koziol J.A., Feng A.C. Prostate brachytherapy seed migration and dosimetry: Analysis of stranded sources and other potential predictive factors. Brachytherapy 2004, 3:10-19.
108. Davis B.J., Pfeifer E.A., Wilson T.M., et al. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol 2000, 164:1661.
109. Davis B.J., Bresnahan J.F., Stafford S.L., et al. Prostate brachytherapy seed migration to a coronary artery found during angiography. J Urol 2002, 168:1103.
110. Nakano M., Uno H., Gotoh T., et al. Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy 2006, 5:127-130.
111. Nguyen B.D., Schild S.E., Wong W.W., et al. Prostate brachytherapy seed embolization to the right renal artery. Brachytherapy 2009, 8:309-312.
112. Zhu A.X., Wallner K.E., Frivold G.P., et al. Prostate brachytherapy seed migration to the right coronary artery associated with an acute myocardial infarction. Brachytherapy 2006, 5:262-265.
113. Reed D.R., Wallner K.E., Merrick G.S., et al. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy 2007, 6:129-134.
114. Heysek R.V., Gwede C.K., Torres-Roca J., et al. A dosimetric analysis of unstranded seeds versus customized stranded seeds in transperineal interstitial permanent prostate seed brachytherapy. Brachytherapy 2006, 5:244-250.
115. Lin K., Lee S.P., Cho J.S., et al. Improvements in prostate brachytherapy dosimetry due to seed stranding. Brachytherapy 2007, 6:44-48.
116. Fagundes H.M., Keys R.J., Wojcik M.F., et al. Transperineal TRUS-guided prostate brachytherapy using loose seeds versus RAPIDStrand: A dosimetric analysis. Brachytherapy 2004, 3:136-140.
117. Crook J. Commentary on " a comparison of the precision of seeds deposited as loose seeds vs. suture-embedded seeds: A randomized trial" and " prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors": to strand or not to strand-is this really the question?. Brachytherapy 2004, 3:20-21.
118. Usmani N., Chng N., Spadinger I., et al. Lack of significant intraprostatic migration of stranded iodine-125 sources in prostate brachytherapy implants. Brachytherapy 2011, 10:275-285.
119. Rivard M.J., Coursey B.M., DeWerd L.A., et al. Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. Med Phys 2004, 31:633-674. [Erratum appears in Med Phys. 2004 Dec;31(12):3532-3533].
120. Al-Qaisieh B., Witteveen T., Carey B., et al. Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 75:626-630.
121. Williamson J.F., Butler W., Dewerd L.A., et al. Recommendations of the American Association of Physicists in Medicine regarding the impact of implementing the 2004 task group 43 report on dose specification for 103Pd and 125I interstitial brachytherapy. Med Phys 2005, 32:1424-1439.
122. Li Z., Das R.K., DeWerd L.A., et al. Dosimetric prerequisites for routine clinical use of photon emitting brachytherapy sources with average energy higher than 50 kev. Med Phys 2007, 34:37-40.
123. Beyer D., Nath R., Butler W., et al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2000, 47:273-275.
124. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 1998, 41:101-108.
125. Papagikos M.A., Deguzman A.F., Rossi P.J., et al. Dosimetric quantifiers for low-dose-rate prostate brachytherapy: Is V(100) superior to D(90)?. Brachytherapy 2005, 4:252-258.
126. Orio P., Wallner K., Merrick G., et al. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol Phys 2007, 67:342-346.
127. Morris W.J., Keyes M., Palma D., et al. Evaluation of dosimetric parameters and disease response after 125 iodine transperineal brachytherapy for low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:1432-1438.
128. Morris W.J., Halperin R., Spadinger I. Point: The relationship between postimplant dose metrics and biochemical no evidence of disease following low dose rate prostate brachytherapy: Is there an elephant in the room?. Brachytherapy 2010, 9:289-292.
129. Merrick G.S., Butler W.M., Wallner K.E., et al. Variability of prostate brachytherapy pre-implant dosimetry: A multi-institutional analysis. Brachytherapy 2005, 4:241-251.
130. Gomez-Iturriaga Pina A., Crook J., Borg J., et al. Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with d(90) ≥180 Gy. Int J Radiat Oncol Biol Phys 2010, 78:422-427.
131. Aronowitz J.N., Crook J.M., Michalski J.M., et al. Inter-institutional variation of implant activity for permanent prostate brachytherapy. Brachytherapy 2008, 7:297-300.
132. Aronowitz J.N., Michalski J.M., Merrick G.S., et al. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy. Am J Clin Oncol 2010, 33:164-167.
133. Bice W.S., Prestidge B.R., Kurtzman S.M., et al. Recommendations for permanent prostate brachytherapy with (131)Cs: A consensus report from the Cesium Advisory Group. Brachytherapy 2008, 7:290-296.
134. Fox K.E., Choe J., Radivoyevitch T., et al. Urinary retention following prostate seed implant brachytherapy following rigid cystoscopy. Int J Radiat Oncol Biol Phys 2010, 78:S354.
135. Smathers S., Wallner K., Korssjoen T., et al. Radiation safety parameters following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 45:397-399.
136. Michalski J., Mutic S., Eichling J., et al. Radiation exposure to family and household members after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 56:764-768.
137. Kleinberg L., Wallner K., Roy J., et al. Treatment-related symptoms during the first year following transperineal 125I prostate implantation. Int J Radiat Oncol Biol Phys 1994, 28:985-990.
138. Huyghe E., Delannes M., Wagner F., et al. Ejaculatory function after permanent 125I prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 74:126-132.
139. Yorozu A., Toya K., Ohashi T., et al. Nippon Igaku Hoshasen Gakkai Zasshi 2005, 65:263-265.
140. Elshaikh M.A., Ulchaker J.C., Reddy C.A., et al. Prophylactic tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: Final report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 2005, 62:164-169.
141. Blasko J.C., Ragde H., Grimm P.D. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 1991, 137:113-118.
142. Hu K., Wallner K. Urinary incontinence in patients who have a TURP/TUIP following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998, 40:783-786.
143. Kollmeier M.A., Stock R.G., Cesaretti J., et al. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. J Urol 2005, 173:808-812.
144. Lee W.R., Roach M., Michalski J., et al. Interobserver variability leads to significant differences in quantifiers of prostate implant adequacy. Int J Radiat Oncol Biol Phys 2002, 54:457-461.
145. Crook J., Milosevic M., Catton P., et al. Interobserver variation in postimplant computed tomography contouring affects quality assessment of prostate brachytherapy. Brachytherapy 2002, 1:66-73.
146. Dubois D.F., Prestidge B.R., Hotchkiss L.A., et al. Intraobserver and interobserver variability of MR imaging- and CT-derived prostate volumes after transperineal interstitial permanent prostate brachytherapy. Radiology 1998, 207:785-789.
147. Dogan N., Mohideen N., Glasgow G.P., et al. Effect of prostatic edema on CT-based postimplant dosimetry. Int J Radiat Oncol Biol Phys 2002, 53:483-489.
148. Waterman F.M., Dicker A.P. Impact of postimplant edema on V(100) and D(90) in prostate brachytherapy: Can implant quality be predicted on day 0?. Int J Radiat Oncol Biol Phys 2002, 53:610-621.
149. Waterman F.M., Dicker A.P. Effect of post-implant edema on the rectal dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 45:571-576.
150. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 1998, 41:1069-1077.
151. Merrick G.S., Butler W.M., Dorsey A.T., et al. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. Radiat Oncol Investig 1998, 6:182-190.
152. Yue N., Chen Z., Peschel R., et al. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants. Int J Radiat Oncol Biol Phys 1999, 45:1063-1072.
153. Ohashi T., Yorozu A., Toya K., et al. Comparison of intraoperative ultrasound with postimplant computed tomography-dosimetric values at Day 1 and Day 30 after prostate brachytherapy. Brachytherapy 2007, 6:246-253.
154. Crook J., McLean M., Yeung I., et al. MRI-CT fusion to assess postbrachytherapy prostate volume and the effects of prolonged edema on dosimetry following transperineal interstitial permanent prostate brachytherapy. Brachytherapy 2004, 3:55-60.
155. Polo A., Cattani F., Vavassori A., et al. MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Radiat Oncol Biol Phys 2004, 60:1572-1579.
156. Tanaka O., Hayashi S., Matsuo M., et al. Comparison of MRI-based and CT/MRI fusion-based postimplant dosimetric analysis of prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006, 66:597-602.
157. Gillan C., Kirilova A., Landon A., et al. Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography. Int J Radiat Oncol Biol Phys 2006, 65:688-693.
158. Merrick G.S., Butler W.M., Wallner K.E., et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002, 54:1055-1062.
159. Buyyounouski M.K., Horwitz E.M., Uzzo R.G., et al. The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys 2004, 59:1383-1391.
160. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
161. Reed D., Wallner K., Merrick G., et al. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 2003, 62:683-688.
162. Chiu-Tsao S.-T., Duckworth T.L., Hsiung C.-Y., et al. Thermoluminescent dosimetry of the SourceTech Medical model STM1251 125I seed. Med Phys 2003, 30:1732-1735.
163. Morris W.J., Berthelet E., Duncan G., et al. ASCENDE-RT*, a randomized trial of brachytherapy: First report of the pilot with a median 52m followup: Cancer outcomes, treatment-related toxicity and patient-reported QOL. Brachytherapy 2008, 7:123.
164. Lee W.R., deGuzman A.F., Bare R.L., et al. Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution. Int J Radiat Oncol Biol Phys 2000, 46:83-88.
165. Acher P., Popert R., Nichol J., et al. Permanent prostate brachytherapy: Dosimetric results and analysis of a learning curve with a dynamic dose-feedback technique. Int J Radiat Oncol Biol Phys 2006, 65:694-698.
166. Merrick G.S., Grimm P.D., Sylvester J., et al. Initial analysis of Pro-Qura: A multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy 2007, 6:9-15.
167. Loiselle C.R., Waheed M., Sylvester J., et al. Analysis of the Pro-Qura Database: Rectal dose, implant quality, and brachytherapist's experience. Brachytherapy 2009, 8:34-39.